By profiling hereditary risk variants in women with breast cancer, researchers hope to lay the foundation for future genetic testing programs in the Caribbean country.
Researchers classified 64 hereditary cancer gene variants with RNA genetic test data, investigating related management changes and potential impacts in other DNA test recipients.
My Gene Counsel's confirmatory testing program is the latest example of how the healthcare system is adapting to consumers' growing appetite for genetic testing.
Ambry researchers recently published a study suggesting that roughly 40 percent of genetic variants reported in raw data from DTC genetic tests may be wrong.
MSK's PathoMAN achieved 94 percent and 81 percent concordance with results from three commercial labs for pathogenic and benign variants, respectively.
The article argues that PRS are bad at identifying those who will develop disease but others say this is the same for widely used risk factors.
CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.
Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.
Genetic counselors, laboratories, and patients themselves have roles to play in reclassifying gene variants, including variants of uncertain significance.
The 72-SNP score is for men of European ancestry who don't have mutations in high penetrance risk genes or mutations in genes associated with aggressive disease.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.